# **Day Break**

Friday, February 14, 2025



#### **Fertilizer**

# **EFERT: 4QCY24 Management Call Takeaways**

- Engro Fertilizer Limited (EFERT) held an investor briefing session to discuss the 4QCY24 financial results and provide key insights on the future outlook for the Company.
- The Company reported consolidated 4QCY24 earnings of PKR 10.3bn (EPS PKR 7.7), down by -8%y/y compared to PKR 11.1bn (EPS PKR 8.3) in the similar period last year. On quarterly basis, profitability was up by +20%q/q during 4QCY24. The Company announced cash dividend of PKR 8.0/share along with the result.
- During CY24, the urea industry sales witnessed a minor decline of -1%y/y
  to clock in 6.6mn tons, however EFERT's urea offtakes declined by -13%y/y
  to ~2.0mn tons mainly due to the major 55-days long turnaround of the
  Enven plant during the 2QCY24.
- The Company highlighted that it inaugurated the fourth Engro Markaz in Muridke. With this addition the Company now operates four Engro Markaz in Muridke, Sahiwal, Sargodha and Sahiwal to ensure availability of highquality fertilizers to farmers at official prices. Regarding the UgAi app, which was launched in October last year, the management commented that it is expected to improve sales.

Engro Fertilizer Limited (EFERT) held an investor briefing session to discuss the 4QCY24 financial results and provide key insights on the future outlook for the Company.

# EFERT reported earnings decline of -8%y/y to PKR 7.70/share during 4OCY24

The Company reported consolidated 4QCY24 earnings of PKR 10.3bn (EPS PKR 7.7), down by -8%y/y compared to PKR 11.1bn (EPS PKR 8.3) in the similar period last year. On quarterly basis, profitability was up by +20%q/q during 4QCY24. The Company announced cash dividend of PKR 8.0/share along with the result bringing total cash payout to PKR 21.5/share for CY24.

#### Key highlights from management conference call

During CY24, the urea industry sales witnessed a minor decline of -1%y/y to clock in 6.6mn tons, however EFERT's urea offtakes declined by -13%y/y to ~2.0mn tons mainly due to the major 55days long turnaround of the Enven plant during the 2QCY24. During the year, the Company's urea market share stood at 31%. On the other hand, the Industry's DAP sales increased by +5%y/y

## **Analyst**

Sakina Makati sakina.makati@igi.com.pk



to 1.6mn tons, while EFERT's offtakes increased by +10%y/y with market share standing at 19%.

- On a quarterly basis, during 4QCY24, the urea industry sales stood at 2.0mn tons and DAP industry sales clocked in at 0.74mn tons. However, the Company's urea market share stood 35% remaining flat on a y/y basis whereas DAP market share declined by -4%y/y to 16%.
- The Company highlighted that it inaugurated the fourth Engro Markaz in Muridke. With this addition the Company now operates four Engro Markaz in Muridke, Sahiwal, Sargodha and Sahiwal to ensure availability of high-quality fertilizers to farmers at official prices. Regarding the UgAi app, which was launched in October last year, the management commented that it is expected to improve sales.
- Regarding the inflated Selling and Distribution charges during the quarter, the Company commented that reclassification of some costs from COGS to S&D coupled with the impact of axle load regime resulted in the surge of S&D expenses during the quarter.
- Regarding the pressure enhancement facility, the Company informed that Scope-1 of the Phase-1 has been completed and Scope-2 is in progress which is expected to be completed during 2QCY25. Whereas, for Phase-II EFERT has started the ordering of compressors.
- The Company also informed that it contributed around PKR
   54.4bn to the national exchequer by way of Government taxes,
   +57% higher than last year.

Important Disclosures at the end of this report



# **Important Disclaimer and Disclosures**

Research Analyst(s) Certification: The Research Analyst(s) hereby certify that the views about the company/companies and the security/ securities discussed in this report accurately reflect his or her or their personal views and that he/she has not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report. The analyst(s) is principally responsible for the preparation of this research report and that he/she or his/her close family/relative does not own 1% or more of a class of common equity securities of the following company/companies covered in this report.

**Disclaimer:** The information and opinions contained herein are prepared by IGI Finex Securities Limited and is for information purposes only. Whilst every effort has been made to ensure that all the information (including any recommendations or opinions expressed) contained in this document (the information) is not misleading or unreliable, IGI Finex Securities Limited makes no representation as to the accuracy or completeness of the information. Neither, IGI Finex Securities Limited nor any director, officer or employee of IGI Finex Securities Limited shall in any manner be liable or responsible for any loss that may be occasioned as consequence of a party relying on the information. This document takes no account of the investment objectives, financial situation and particular needs of investors, who shall seek further professional advice before making any investment decision. The subject Company (ies) is a client of the IGI Finex Securities Limited and IGI Finex Securities offers brokerage services to Subject Company (ies) on a regular basis, in line with industry practice. This document and the information may not be reproduced, distributed or published by any recipient for any purpose. This report is not directed or intended for distribution to, or use by any person or entity not a client of IGI Finex Securities Limited, else directed for distribution.

Rating system: IGI Finex Securities employs three tier ratings system, depending upon expected total return (return is defined as capital gain exclusive of tax) of the security in stated time period, as follows:

# **Recommendation Rating System**

Buy if target price on aforementioned security (ies) is more than 10%, from its last closing price(s) Hold if target price on aforementioned security (ies) is in between -10% and 10%, from its last closing price(s) Sell if target price on aforementioned security (ies) is less than -10%, from its last closing price(s)

Valuation Methodology: To arrive at Target Prices, IGI Finex Securities uses different valuation methodologies including

- Discounted Cash Flow (DCF)
- Reserve Based DCF
- Dividend Discount Model (DDM)
- Justified Price to Book
- Residual Income (RI)
- Relative Valuation (Price to Earning, Price to Sales, Price to Book)

**Risk:** Investment in securities are subject to economic risk, market risk, interest rate risks, currency risks, and credit risks, political and geopolitical risks. The performance of company (ies) covered herein might unfavorably be affected by multiple factors including, business, economic, and political conditions. Hence, there is no assurance or guarantee that estimates, recommendation, opinion, etc. given about the security (ies)/company (ies) in the report will be achieved.

Basic Definitions and Terminologies used: Target Price: A price target is the projected price level of a financial security stated by an investment analyst or advisor. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment, Last Closing: Latest closing price, Market Cap.: Market capitalization is calculated by multiplying a company's shares outstanding by current trading price. EPS: Earnings per Share. DPS: Dividend per Share. ROE: Return on equity is the amount of net income returned as a percentage of shareholders' equity. P/E: Price to Earnings ratio of a company's share price to its per-share earnings. P/B: Price to Book ratio used to compare a stock's market value to its book value. DY: The dividend yield is dividend per share, divided by the price per share.

IGI Finex Securities Limited
Research Analyst(s)
Research Identity Number: R

Research Identity Number: BRP009

© Copyright 2024 IGI Finex Securities Limited



# **Contact Details**

# **Equity Sales**

Zaeem Haider Khan	Head of Equities	Tel: (+92-42) 35301405	zaeem.haider@igi.com.pk
Muhammad Naveed	Regional Manager (Islamabad & Upper North)	Tel: (+92-51) 2604861-62	muhammad.naveed@igi.com.pk
Syeda Mahrukh Hameed	Branch Manager (Lahore)	Tel: (+92-42) 38303564	mahrukh.hameed@igi.com.pk
Shakeel Ahmad	Branch Manager (Faisalabad)	Tel: (+92-41) 2540843-45	shakeel.ahmad1@igi.com.pk
Asif Saleem	Equity Sales (RY Khan)	Tel: (+92-68) 5871652-56	asif.saleem@igi.com.pk
Mehtab Ali	Equity Sales (Multan)	Tel: (+92-61) 4512003	mahtab.ali@igi.com.pk

## **Research Team**

Abdullah Farhan	Head of Research	Tel: (+92-21) 111-234-234 Ext: 912	abdullah.farhan@igi.com.pk
Sakina Makati	Research Analyst	Tel: (+92-21) 111-234-234 Ext: 810	sakina.makati@igi.com.pk
Laraib Nisar	Research Analyst	Tel: (+92-21) 111-234-234 Ext: 974	laraib.nisar@igi.com.pk

## **IGI Finex Securities Limited**

Trading Rights Entitlement Certificate (TREC) Holder of Pakistan Stock Exchange Limited | Corporate member of Pakistan Mercantile Exchange Limited Website: www.igisecurities.com.pk

## **Head Office**

Suite No 701-713, 7th Floor, The Forum, G-20, Khayaban-e-Jami Block-09, Clifton, Karachi-75600 UAN: (+92-21) 111-444-001 | (+92-21) 111-234-234 Fax: (+92-21) 35309169, 35301780

Lahore Office	Islamabad Office	
Shop # G-009, Ground Floor,	3 <sup>rd</sup> Floor, Kamran Centre,	
Packages Mall	Block- B, Jinnah Avenue, Blue Area	
Tel: (+92-42) 38303560-69	Tel: (+92-51) 2604861-2, 2604864, 2273439	
Fax: (+92-42) 38303559	Fax: (+92-51) 2273861	
Faisalabad Office	Rahim Yar Khan Office	
Office No. 2, 5 & 8, Ground Floor, The	Plot # 12, Basement of Khalid Market,	
Regency International 949, The Mall	Model Town, Town Hall Road	
Faisalabad	Tel: (+92-68) 5871652-3	
Tel: (+92-41) 2540843-45	Fax: (+92-68) 5871651	
Multan Office		
Mezzanine Floor, Abdali Tower,		
Abdali Road		
Tel: (92-61) 4512003, 4571183		

IGI Finex Securities Limited Research Analyst(s)

Research Identity Number: BRP009

© Copyright 2024 IGI Finex Securities Limited